Biomaterials Market Share

North America Market Insights 

North America is dominating the market and is expected to hold the market share of 39.2% at a CAGR of 8.1% by 2037. The market is driven by strong R&D investments, government healthcare spending, and the wide adoption of advanced medical implants. The region has benefited from the advanced regulatory policies with the FDA fast-tracking approvals for patient-specific and biodegradable biomaterials to aid the innovation in tissue engineering and regenerative medicines. Furthermore, partnerships among universities, start-ups, and multinational producers of medical devices are promoting technological transfer and commercialization, establishing North America as a global leader in the use of biomaterials.

The market in the U.S. is driven by rise in orthopedics, cardiology, and regenerative treatments. NIH has spent over USD 5.5 billion in 2023 on biomaterials research and translational medicines with a rise of 7.5% since 2021. Medicaid in 2024 allocated USD 1.7 billion, which increased access to synthetic biomaterials and dental prosthetics by 10.4%. Further, Medicare expenditures increased by 15.7% from 2020 to 2024, with USD 800.8 million, spurred by revised reimbursement structures for implantable devices and surgery using biomaterials. Rising domestic manufacturing and the FDA's simplified combination device guidance have decreased time-to-approval for biomaterial-device combination hybrids. The U.S. continues to be a net importer of nanomaterials and bioengineered polymers but is enhancing scalability for additive manufacturing.

Asia Pacific Market Insights

The APAC is the fastest-growing region in the market and is expected to have a market revenue share of 23.5% at a CAGR of 8.7% by 2037. The market is driven by the increase in surgical demand, demographic shifts, and long-term investments in implantable and regenerative medical technologies. The critical pillars leading the biomaterial market in the APAC region are Japan, China, India, Malaysia, and South Korea are expanding with clinical application of biomaterials across dental, cardiovascular, orthopedic, and tissue engineering domains and government-backed R&D initiatives.

Japan holds the largest share in the market in the APAC region and is poised to have a revenue share of 10.8% by 2024. The Ministry of Health, Labour and Welfare and Agency for Medical Research and Development in Japan together allocated 12.4% of the national healthcare budget to biomaterials applications in 2024. This stricken a USD 3.4 billion rise while comparing with the market in 2022, hence, this rise is driven by the demand for cardiovascular devices, orthopedic implants and regenerative therapies among the elderly population. The market in Japan further accelerates with the clinical adoption and domestic R&D in biomaterials.

Europe Market Insights

The biomaterials market in Europe is significantly expanding and is projected to hold the market share of 28.4% at a CAGR of 7.6% by 2037. The rise is driven by the rising demand for orthopedic implants, regenerative medicine, and cardiovascular devices. The public healthcare budgets are expanding with government initiatives and the elderly population, making the market expand. Furthermore, start-ups, partnerships among universities, and multinational companies of medical devices are promoting technological transfer and commercialization, establishing Europe as a global leader in the use of biomaterials.

Germany holds the largest share in the biomaterials market and is anticipated to have a share of 11.6% by 2037. The market in Germany is driven by the advanced infrastructure, sustained investments and high volume of cardiovascular and orthopedic surgeries. Large-scale hospital integration and bioengineered implant procurement are still supported by the German Medical Association (BÄK) and the Federal Ministry of Health (BMG). Further Germany invested nearly €4.5 billion in biomaterials which is a 12.8% rise since 2021. The rise impacts the increase in dental restoration, cardiovascular stents and joint replacements.

Europe Government Investment Table (2021–2025)